No Data
Three consecutive boards HPGC Renmintongtai Pharmaceutical Corporation (600829.SH): Main Business has not undergone significant changes.
HPGC Renmintongtai Pharmaceutical Corporation (600829.SH) issued a risk warning announcement, the company is a pharmaceutical distribution enterprise, mainly engaged in the operation of pharmaceutical wholesale...
Are Robust Financials Driving The Recent Rally In HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Stock?
Improved Earnings Required Before HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Stock's 30% Jump Looks Justified
Third Quarter Report 2024
hpgc renmintongtai pharmaceutical corporation (600829.SH) released its performance for the first three quarters, with a net income of 0.206 billion yuan, a 14.36% year-on-year decrease.
hpgc renmintongtai pharmaceutical corporation (600829.SH) disclosed the third quarter report for 2024, achieving revenue of 76...
hpgc renmintongtai pharmaceutical corporation (600829.SH): net income in the first three quarters was 0.206 billion yuan, a year-on-year decrease of 14.36%.
Gelonghui October 21st丨Hpgc Renmintongtai Pharmaceutical Corporation (600829.SH) released the third quarter report, with revenue of 7.678 billion yuan, a year-on-year decrease of 1.88%, net income of 0.206 billion yuan, a year-on-year decrease of 14.36%, non-GAAP net income of 0.19 billion yuan, a year-on-year decrease of 17.16%, and basic earnings per share of 0.3552 yuan.
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
